Biocon Limited

rs,

, 2025 To, The Secretary BSE Limited Department of Corporate Services, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523 Dear Sir/Madam, To, The Secretary National

₹4,500 crore

ing Remarks Opening Remarks: Q1 FY26 Performance Overview Equity Fundraise: Successfully raised ₹4,500 crores through QIP, first equity fundraise since IPO in 2004 Funds will be used to increase stake in Bio

2 %

Q1 FY26 In ₹ Cr Generics Biosimilars CRDMO# Revenue from Operations Total Revenue Core EBITDA2 % Margin R&D (Net) % of Revenue (Ex. Syngene) EBITDA % Margin Profit Before Tax (Before except

₹1,057

een renamed as CRDMO, representing Syngene’s business 1 Includes Income from BFI divestment gain - ₹1,057 Cr | 2 Core EBITDA defined as EBITDA before forex, R&D, licensing income, BFI divestment gain, and m

9%

arter reflects ramp-up costs associated with operationalizing new facilities % of Total Revenue 9% 18% 31% R&D investments at 10% of revenue, primarily focused on GLP-1 portfolio advancement. R

18%

r reflects ramp-up costs associated with operationalizing new facilities % of Total Revenue 9% 18% 31% R&D investments at 10% of revenue, primarily focused on GLP-1 portfolio advancement. R & D

31%

lects ramp-up costs associated with operationalizing new facilities % of Total Revenue 9% 18% 31% R&D investments at 10% of revenue, primarily focused on GLP-1 portfolio advancement. R & D 70

10%

ciated with operationalizing new facilities % of Total Revenue 9% 18% 31% R&D investments at 10% of revenue, primarily focused on GLP-1 portfolio advancement. R & D 70 64 83 9 (15) PBT imp

8%

impacted by higher interest and depreciation costs linked to recent capex % of Revenue 10% 10% 8% EBITDA 1 59 243 (99) (100) % of Total Revenue 0% 9% 23% Biosimilars Biocon Biologics:

0%

to recent capex % of Revenue 10% 10% 8% EBITDA 1 59 243 (99) (100) % of Total Revenue 0% 9% 23% Biosimilars Biocon Biologics: Q1 FY26 Business Performance update Focus in FY26 • Sca

23%

t capex % of Revenue 10% 10% 8% EBITDA 1 59 243 (99) (100) % of Total Revenue 0% 9% 23% Biosimilars Biocon Biologics: Q1 FY26 Business Performance update Focus in FY26 • Scaling comm

36%

arkets Financial Performance • • • 18% YoY growth driven by robust product demand across markets 36% YoY growth in EBITDA on a like-for-like basis EBITDA margin (excluding forex and other items) at 24

“Successfully raised ₹4,500 crores through QIP, first equity fundraise since IPO in 2004 Funds will be used to increase stake in Biocon Biologics & provide an exit to private equity investors Product Launches & Approvals: Received US FDA approval for Kirsty (bInsulin Aspart), the first interchangeable rapid-acting insulin in the U.S.”

“Biocon earned a ‘Gold’ rating in the 2024 EcoVadis assessment with an improved score of 77 from 70 in 2023 Syngene recognized as one of the “World’s Most Sustainable Companies 2025” by TIME Magazine and Statista, ranked #1 in Indian Pharma & Biotech and top 20 globally within its sector Q1 FY26 Financial Highlights Financial Highlights – Q1 FY26 In ₹ Cr Generics Biosimilars CRDMO# Revenue from Operations Total Revenue Core EBITDA2 % Margin R&D (Net) % of Revenue (Ex.”

“In ₹ Cr Segment Revenue Q1 FY26 Q1 FY25 Q4 FY25 YoY% QoQ% 697 659 1,048 6 (33) Core EBITDA 64 123 326 (48) (80) EBITDA for the quarter reflects ramp-up costs associated with operationalizing new facilities % of Total Revenue 9% 18% 31% R&D investments at 10% of revenue, primarily focused on GLP-1 portfolio advancement.”

“R & D 70 64 83 9 (15) PBT impacted by higher interest and depreciation costs linked to recent capex % of Revenue 10% 10% 8% EBITDA 1 59 243 (99) (100) % of Total Revenue 0% 9% 23% Biosimilars Biocon Biologics: Q1 FY26 Business Performance update Focus in FY26 • Scaling commercialised products • Deepening presence in key markets • Preparing for future launches to drive sustainable and profitable growth North America Highlights • Received U.S.”

“Biologics CRDMO market Outlook: Strong start to FY26 Biosimilars: Well-positioned for accelerated growth with recent launches and approvals CRDMO: Continues to benefit from favorable demand trends, actively investing to future-proof its capabilities Generics: Early investments in GLP-1s and peptide APIs are gaining traction; upcoming launches to fuel double-digit growth for the full year Q&A”

Equity Fundraise

1

Sustainability

1

Equity Fundraise

Successfully raised ₹4,500 crores through QIP, first equity fundraise since IPO in 2004 Funds will be used to increase stake in Biocon Biologics & provide an exit to private equity investors Product Launches & Approvals: Received US FDA approval for Kirsty (bInsulin Aspart), the first interchangeable rapid-acting insulin in the U.S. Launched Yesafili , the first biosimilar Aflibercept launch in Canada Secured EC and MHRA, UK approvals for bDenosumab, marks Biocon Biologics anticipated entry into bone health, a new therapeutic segment Facility Expansions & Strategic Capability Building: GLP-1-focused injectable facility commissioned Syngene has opened a new state-of-the-art peptide laboratory which complements existing platforms Recently acquired Cranbury and Bayview facilities will play a critical role in ensuring supply chain resilience, regulatory proximity and secure U.S. market access for our businesses

Sustainability

Biocon earned a ‘Gold’ rating in the 2024 EcoVadis assessment with an improved score of 77 from 70 in 2023 Syngene recognized as one of the “World’s Most Sustainable Companies 2025” by TIME Magazine and Statista, ranked #1 in Indian Pharma & Biotech and top 20 globally within its sector Q1 FY26 Financial Highlights Financial Highlights – Q1 FY26 In ₹ Cr Generics Biosimilars CRDMO# Revenue from Operations Total Revenue Core EBITDA2 % Margin R&D (Net) % of Revenue (Ex. Syngene) EBITDA % Margin Profit Before Tax (Before exceptional items) % Margin Net Profit (Before exceptional items) Exceptional item, net of tax & NCI Net Profit (Reported) Q1 FY26 Q1 FY25 Q4 FY25 YoY%3 QoQ% 697 2,458 875 3,942 4,022 1,003 25 205 7 829 21 97 2 31 - 31 659 2,083 790 3,433 4,5671 903 26 228 9 1,7551 381 1,1141 241 6481,4 12 6601,4 1,048 2,463 1,018 4,417 4,454 1,363 31 231 7 1,115 25 466 10 333 11 344 6 18 11 15 15 11 (10) 19 72 342 65 (33) 0 (14) (11) (10) (26) (11) (26) (79) (91) (91) @ Our Research Servi